Bob71
Nuovo Utente
- Registrato
- 30/10/02
- Messaggi
- 2.467
- Punti reazioni
- 49
Non so se qualcuno la stia seguendo 
mi farebbe piacere qualche commento se possibile grazie 
Inovio Biomedical Announces Needle-Free Electroporation Patent
Wednesday February 14, 6:00 am ET
SAN DIEGO--(BUSINESS WIRE)--Inovio Biomedical Corp. (AMEX:INO - News), which is focused on the development of DNA vaccines and a novel tumor ablation therapy, announced today that the US Patent and Trademark Office has issued to Genetronics, Inc., Inovio's wholly-owned subsidiary, US Patent number 7,171,264, titled "Intradermal Delivery of Active Agents by Needle-Free Injection and Electroporation."
ADVERTISEMENT
This patent adds to Inovio's growing patent estate relating to the delivery of genes and drugs to a variety of tissues. It specifically claims a novel method of delivering biological material, including DNA vaccines, to skin using a needle-free method of electroporation. Electroporation uses brief, controlled electrical pulses to dramatically increase cellular uptake of a useful biopharmaceutical.
"Enabling skin delivery of DNA vaccines may provide Inovio with a convenient alternative to current intramuscular electroporation methods for certain types of DNA vaccines and could broaden the opportunities for our technology," stated Avtar Dhillon, MD, President and CEO of Inovio. "Development of a needle-free delivery system is just one of the exciting projects we are pursuing in our continuing advancement of electroporation technology for DNA vaccination."
mi farebbe piacere qualche commento se possibile grazie Inovio Biomedical Announces Needle-Free Electroporation Patent
Wednesday February 14, 6:00 am ET
SAN DIEGO--(BUSINESS WIRE)--Inovio Biomedical Corp. (AMEX:INO - News), which is focused on the development of DNA vaccines and a novel tumor ablation therapy, announced today that the US Patent and Trademark Office has issued to Genetronics, Inc., Inovio's wholly-owned subsidiary, US Patent number 7,171,264, titled "Intradermal Delivery of Active Agents by Needle-Free Injection and Electroporation."
ADVERTISEMENT
This patent adds to Inovio's growing patent estate relating to the delivery of genes and drugs to a variety of tissues. It specifically claims a novel method of delivering biological material, including DNA vaccines, to skin using a needle-free method of electroporation. Electroporation uses brief, controlled electrical pulses to dramatically increase cellular uptake of a useful biopharmaceutical.
"Enabling skin delivery of DNA vaccines may provide Inovio with a convenient alternative to current intramuscular electroporation methods for certain types of DNA vaccines and could broaden the opportunities for our technology," stated Avtar Dhillon, MD, President and CEO of Inovio. "Development of a needle-free delivery system is just one of the exciting projects we are pursuing in our continuing advancement of electroporation technology for DNA vaccination."
